Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Diemert

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine primingAllan C deCamp, Martin M Corcoran, William J Fulp, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
Science (New York, N.Y.)|December 1, 2022
Vaccination induces HIV broadly neutralizing antibody precursors in humansDavid J Leggat, Kristen W Cohen, Jordan R Willis, et al.
Research Square|May 19, 2023
Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) TrialAngela Branche, Nadine Rouphael, David Diemert, et al.
Science (New York, N.Y.)|May 15, 2025
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humansJordan R Willis, Madhu Prabhakaran, Michelle Muthui, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine primingAllan C deCamp, Martin M Corcoran, William J Fulp, et al.
The Lancet. Infectious Diseases|January 29, 2022
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre studySaranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, et al.
Science (New York, N.Y.)|December 1, 2022
Vaccination induces HIV broadly neutralizing antibody precursors in humansDavid J Leggat, Kristen W Cohen, Jordan R Willis, et al.
Research Square|May 19, 2023
Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) TrialAngela Branche, Nadine Rouphael, David Diemert, et al.
Science (New York, N.Y.)|May 15, 2025
Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humansJordan R Willis, Madhu Prabhakaran, Michelle Muthui, et al.
Pageof 4